Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Tarrytown-based Regeneron Pharmaceuticals has reported financial results for its second quarter of 2025. Net revenues increased 4% from the $3.54 ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Second Quarter 2025 Results Key Financial Results Revenue: US$3.68b (up ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its ...

Regeneron Pharmaceuticals (REGN) is gearing up for an earnings announcement that could pivot its stock's current trajectory.

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

Regeneron (REGN) came out with quarterly earnings of $12.89 per share, beating the Zacks Consensus Estimate of $8.03 per ...